Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VIVUS, Inc.    

VIVUS, INC.
My previous session
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2018 59,0 M
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
Sales 2019 60,0 M
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0,69x
Capi. / Sales2019 0,68x
Capitalization 40,6 M
More Financials
Company
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products.Its products include Qsymia and STENDRA/SPEDRA. The company was founded by Virgil A. Palace in April 16, 1991 and is headquartered in Mountain View, CA. 
Sector
Pharmaceuticals
Calendar
11/07Earnings Release
More about the company
Latest news on VIVUS, INC.
10/17VIVUS INC : Entry into a Material Definitive Agreement, Other Events, Financial ..
AQ
10/10VIVUS to Present at the BIO Investor Forum on October 17, 2018
GL
09/26VIVUS INC : Regulation FD Disclosure, Other Events, Financial Statements and Exh..
AQ
09/26VIVUS Regains Compliance with Nasdaq Listing Requirements
GL
09/24VIVUS to Present at the Fourth Annual Robins Equity Research Round-Up
GL
09/21VIVUS INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/21VIVUS Supports the Cystic Fibrosis Community Through Sponsorship of and Parti..
GL
09/11VIVUS : Announces 1-for-10 Reverse Stock Split
AQ
09/11VIVUS, INC. : REVERSE SPLIT: 1 of 10
FA
09/10VIVUS INC : Material Modification to Rights of Security Holders, Amendments to A..
AQ
More news
Sector news : Biopharmaceuticals
04:17pAstraZeneca Adds Cancer Drugs to Pipeline with Innate Pharma Deal
DJ
03:33pPFIZER : Bain Capital Create Company to Develop Drugs for CNS Disorders -- Updat..
DJ
03:13pPFIZER : Bain Capital Create New CNS Company
DJ
02:44pCSL : Seqirus Gets FDA Approval for Afluria Quadrivalent in Young Children
DJ
01:29pBIOGEN : 3Q Profit Rises 18%; Beats Expectations
DJ
More sector news : Biopharmaceuticals
MarketScreener Strategies on VIVUS, INC. 
VIVUS - 2013
Bearish trend should continue
SELL
More Strategies
News from SeekingAlpha
09/12Midday Gainers / Losers (09/12/2018) 
09/10VIVUS TO REVERSE SPLIT SHARES 1 : 10 after the close; post-split trading to comm.. 
08/07Vivus' (VVUS) CEO John Amos on Q2 2018 Results - Earnings Call Transcript 
08/07Vivus misses by $0.01, misses on revenue 
07/12YOUR DAILY PHARMA SCOOP : Kamada Phase 3 Approved, Vivus Positive, IsoRay Down 
Chart VIVUS, INC.
Duration : Period :
VIVUS, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 1
Average target price 10,0 $
Spread / Average Target 162%
EPS Revisions
Managers
NameTitle
John P. Amos Chief Executive Officer & Director
Kenneth Suh President
David York Norton Chairman
Scott Oehrlein Chief Operating Officer
Mark K. Oki Chief Financial & Accounting Officer
Sector and Competitors
1st jan.Capitalization (M$)
VIVUS, INC.1,054.00%46
BIOGEN-0.95%66 506
CSL LIMITED33.09%60 790
ALEXION PHARMACEUTICALS3.62%28 205
BIOMARIN PHARMACEUTICAL16.10%18 437
GRIFOLS-5.34%16 648